Humacyte is trading at $0.44, up 10.75%, amid stronger biotech sentiment, though no clear company-specific announcement explains the November 6 rise. - Humacyte’s third-quarter results and business update are scheduled for November 10 and have not been released today. - The biotech sector is up 2.01%; Moderna’s earnings beat and raised outlook drew attention to the sector. - A broader-market rebound may also be supportive, but available evidence does not establish a single direct catalyst for Humacyte.